Caribou Biosciences, Inc.
CRBU · Biological Products, (No Diagnostic Substances) · 99.2M shares · +42%/yr ↑ dilution · EDGAR filings ↗
Reference price $1.93 · est. market cap ~$191M — last insider sale, 2026-02-25 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D44Clinical/early-stage biotech — CRISPR cell-therapy clinical, heavy burn ($112M), funded.
Strengths
- Liquidity — current ratio 5.7 (58th)
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical & funding risk — per 10-K
Notable findings
- Chronic dilutionShare count +42%/yr over 3y (dilution, book value/share -86%)
- Cash burnNegative free cash flow (-112.4M)
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Net lossNet loss (net margin -1327.4%)
- Trial resultTrial topline data reported — see 8-K for outcome 8-K ↗
- Insider sellingInsider selling — 5 open-market sale(s) by 4 insider(s) (cluster of 4 insiders, last 6mo) Form 4 ↗
- Revenue declineRevenue -39.2% YoY
- Notable holderHeld by 5 notable fund(s): RENAISSANCE TECHNOLOGIES LLC, FMR LLC, STATE STREET CORP +2 more (as of 2026-03-31)
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Operating margin
-1329.4%
Net margin
-1327.4%
Return on equity
-121.2%
Return on assets
-84.5%
Revenue growth (QoQ)
-39.2%
Current ratio
5.7×
Free cash flow
-$112M
EBITDA
-$145M
Tangible book value
$122M
Cash & investments
$146M
Cash runway
5q
Stock comp / revenue
113.6%
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-02-25 | Kelly Timothy P | Sell | 6.2K | $1.93 |
| 2026-02-24 | Kelly Timothy P | Sell | 3.1K | $1.96 |
| 2026-02-24 | Khan Ruhi Ahmad | Sell | 6.9K | $1.96 |
| 2026-02-24 | MCCLUNG BARBARA G | Sell | 6.9K | $1.96 |
| 2026-02-24 | Albertson Tina M. | Sell | 1.1K | $1.96 |
| 2026-02-20 | Ryali Sriram | Grant | 55K | — |
| 2026-02-20 | Haurwitz Rachel E. | Grant | 152K | — |
| 2026-02-20 | Albertson Tina M. | Grant | 55K | — |
| 2026-02-20 | Khan Ruhi Ahmad | Grant | 45K | — |
| 2026-02-20 | Kelly Timothy P | Grant | 45K | — |
| 2026-02-20 | MCCLUNG BARBARA G | Grant | 45K | — |
| 2025-03-14 | Haurwitz Rachel E. | Buy | 20K | $1.02 |
| 2025-02-21 | Kanner Steven | Sell | 3.6K | $1.35 |
| 2025-02-21 | Khan Ruhi Ahmad | Sell | 3.6K | $1.35 |
| 2025-02-21 | MCCLUNG BARBARA G | Sell | 3.6K | $1.35 |
| 2025-02-20 | Kelly Timothy P | Grant | 38K | — |
| 2025-02-20 | Haurwitz Rachel E. | Grant | 137K | — |
| 2025-02-20 | MCCLUNG BARBARA G | Grant | 38K | — |
| 2025-02-20 | Albertson Tina M. | Grant | 15K | — |
| 2025-02-20 | Khan Ruhi Ahmad | Grant | 38K | — |
| 2025-02-20 | Kanner Steven | Grant | 38K | — |
| 2025-01-29 | Ryali Sriram | Buy | 17K | $1.42 |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT05332054 ↗ | Long-Term Follow-up Study Lymphoma, Non-Hodgkin, Relapsed Non-Hodgkin Lymphoma | — | Enrolling By Invitation | 2041-12-01 |
| NCT05722418 ↗ | CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma Relapsed/Refractory Multiple Myeloma | PHASE1 | Recruiting | 2027-12-01 |
| NCT06752876 ↗ | CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP) Systemic Lupus Erythematosus, Lupus | PHASE1 | Withdrawn | 2029-04-01 |
| NCT04637763 ↗ | CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma | PHASE1 | Unknown | 2025-08-01 |
| NCT06128044 ↗ | CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | PHASE1 | Terminated | 2025-05-30 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-06-18 | Shareholder voteExhibits | filing ↗ |
| 2026-06-11 | Reg FDOtherExhibits | filing ↗ |
| 2026-05-07 | ResultsExhibits | filing ↗ |
| 2026-03-31 | Reg FDOtherExhibits | filing ↗ |
| 2026-03-05 | ResultsExhibits | filing ↗ |
| 2025-11-12 | ResultsExhibits | filing ↗ |
| 2025-11-03 | ResultsReg FDOtherExhibits | filing ↗ |
| 2025-08-12 | ResultsExhibits | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-18 | 2026-06-17 | 0001619856-26-000047 ↗ |
| 8-K | 2026-06-11 | 2026-06-11 | 0001619856-26-000043 ↗ |
| 10-Q | 2026-05-07 | 2026-03-31 | 0001619856-26-000036 ↗ |
| 8-K | 2026-05-07 | 2026-05-07 | 0001619856-26-000035 ↗ |
| 8-K | 2026-03-31 | 2026-03-31 | 0001619856-26-000012 ↗ |
| 8-K | 2026-03-05 | 2026-03-05 | 0001619856-26-000007 ↗ |
| 10-K | 2026-03-05 | 2025-12-31 | 0001619856-26-000008 ↗ |
| 10-Q | 2025-11-12 | 2025-09-30 | 0001619856-25-000071 ↗ |
| 8-K | 2025-11-12 | 2025-11-12 | 0001619856-25-000070 ↗ |
| 8-K | 2025-11-03 | 2025-11-03 | 0001619856-25-000065 ↗ |
| 8-K | 2025-08-12 | 2025-08-12 | 0001619856-25-000060 ↗ |
| 10-Q | 2025-08-12 | 2025-06-30 | 0001619856-25-000061 ↗ |